28/03/2024 09:44

Pro Medicus Ltd (PME) $102.54

Medical software business PME has enjoyed a stellar advance since mid-2022, but as its valuation stretched higher, it became vulnerable to a correction, which unfolded in February even after delivering explosive earnings growth.

Read more

09/02/2024 09:29

Pro Medicus Ltd (PME) $106.92

Medical software business PME has been a standout performer since COVID, but after reaching $110 this week, it feels like a lot of good news is baked into this particular cake – although we’ve said this before! This is a high-quality and high-growth business which is appealing into pullbacks, which we should remember are regular occurrences for stocks that have more than doubled in a relatively short time.  

Read more

26/09/2023 16:49

Pro Medicus (PME) $80.01

PME +12.39%: the medical software company jumped to all-time highs today on the back of a nice contract win. The $140m 10-year deal with Baylor Scott & White Health BSWH) is the company’s first in Texas where BSWH is the largest not-for-profit healthcare provider with around 500 radiologists.

Read more

01/02/2022 09:31

Pro Medicus Ltd (PME) $45.10

PME has fallen 28.3% making it the worst performing stock on the ASX200 so far this year with the trouble all around valuation as opposed to business quality. While P/E’s are fairly irrelevant for these sorts of stocks, 110x 2022 earnings is a number to keep in one’s mind but probably more telling is their price to sales multiple P/S which sits 69x. We like...

Read more

19/08/2021 09:34

Pro Medicus Ltd (PME) $65.35

Healthcare imaging company PME delivered a cracking full-year result yesterday sending the stock soaring over 15% to fresh all-time highs. Everything read well with revenue up almost 20% and NPAT rising over 33% to $30.9m, the company also announced  a 8c dividend although with a yields close to that on offer at the bank this stocks clearly...

Read more

28/05/2021 09:29

Pro Medicus Ltd (PME) $44.93

Imaging business PME has been a strong performer post COVID with its strong half-year result delivered in March confirming the business is kicking goals – revenue was up almost 8% to $31.6m while profit was just shy of $20m. We think PME is very likely to test $50 over the next 12-months but the risk / reward is only compelling under $40.

Read more